A lot of people questioned Bahija Jallal’s decision to join the UK independent biotech Immunocore, Ltd.as its CEO in January 2019. She was installed as the highly regarded leader of AstraZeneca PLC’s biologics R&D arm, MedImmune LLC, which coincidentally ceased to operate in just a month later under the auspices of its parent company’s restructuring.
The Oxford-based biotech was a “diamond in the rough” she told In Vivo, “they could not see what I saw...